BrainScope to Showcase New-to-Market Medical Technology at Momentum 2017: UCAOA Urgent Care Convention and Expo
Bethesda, MD – BrainScope Company, Inc. today announced it will unveil its new FDA-cleared, objective comprehensive head injury assessment device, BrainScope One, at Momentum 2017: UCAOA Urgent Care Convention and Expo from April 30 to May 3 at the Gaylord Resort and Convention Center in National Harbor, Maryland.
BrainScope One is a revolutionary medical technology that gives urgent care physicians and staff greater assurance to objectively assess the full spectrum of brain injury, including concussion. This handheld, easy-to-use product was recently rebranded by the company from the Ahead 300 to BrainScope One. Using EEG-based technology that is non-invasive and pain-free for patients 18-85 years old and within 3 days after head injury, BrainScope One measures and interprets brain electrical activity and a patient’s neurocognitive function, creating a panel of objective data – a powerful tool for urgent care physicians to make their clinical diagnosis.
The opportunity by using BrainScope One for urgent care centers is significant. Five million patients are seen in U.S. Emergency Departments each year with closed head injuries, and millions more do not seek evaluation. Further, according to recent publications, 95% of all head-injured patients who visit the ED, present with mild symptoms. The vast majority of these patients receive a CT scan, of whom over 90% are CT negative for structural brain injury, creating needless radiation exposure to patients. BrainScope One has the potential to significantly reduce costs, radiation exposure and wait times associated with hospital visits and unneeded CT scans.
“We are thrilled to be showcasing BrainScope One to attendees at the UCAOA Urgent Care Convention and Expo. This innovative medical technology can have a substantial impact on how clinicians at urgent care clinics across the country can achieve superior patient care, operate with great efficiency, and discover a new revenue source for rapid assessment of brain injury," said Michael Singer, Chief Executive Officer of BrainScope.
Now available to urgent care professionals across the country, BrainScope One is easy-to-use and brings many advantages to urgent care clinics, such as:
• Increased physician assurance and patient confidence with the highest quality of care
• Enhanced operational efficiencies
• New opportunities for growth
“BrainScope One can easily be integrated into existing urgent care clinics’ workflow and offers new economic opportunities by providing the necessary technology to serve patients who have suffered a head injury," stated Andrew Holman, Chief Commercial Officer of BrainScope. “The clinical and economic benefits to urgent care centers are considerable."
Physicians speaking on behalf of BrainScope at the upcoming UCAOA Urgent Care Convention and Expo include: Dr. Garrett Bomba, Medical Director of Urgent Care Services and Dr. Leslie Prichep, Chief Scientific Officer at BrainScope.
BrainScope is a medical neurotechnology company that has developed a new generation of handheld, easy-to-use, non-invasive devices designed to aid medical professionals in rapidly and objectively assessing various neurological conditions, beginning with traumatic brain injury (TBI), including concussion. The company’s first product introduced in 2017, BrainScope One, uses EEG-based technology that is non-invasive and pain-free for patients 18-85 years old and within 3 days after head injury. BrainScope One measures and interprets brain electrical activity and a patient’s neurocognitive function creating a panel of objective data to help physicians make their clinical diagnosis. BrainScope’s technology platform integrates databases of thousands of brainwave recordings with advanced digital signal processing, sophisticated algorithms, miniaturized hardware and disposable headset sensors, which are all covered by an extensive intellectual property portfolio of over 100 issued and pending patents. BrainScope has received four FDA clearances and ISO 13485:2003 Certification. BrainScope has partnered with the U.S. Department of Defense for the development of its TBI assessment technology, and was named both an original recipient and final awardee of the GE-NFL Head Health Challenge I. BrainScope has also received significant funding from private investors to accelerate its development efforts, with backing from Revolution (created by AOL co-founder Steve Case), ZG Ventures, Maryland Venture Fund, Brain Trust Accelerator Fund, and Difference Capital. For more information, please visit www.brainscope.com.